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What is the key question? 
Can antibodies be used to identify cystic fibrosis patients with Mycobacterium abscessus 
complex?  
What is the bottom line? 
Patients with pulmonary disease caused by M. abscessus complex had significantly elevated 
antibody levels specific for this pathogen, compared to patients with previous or no infection.   
Why read on? 
The new antibody assay was easy to perform and the test quickly identified high risk patients in 
need of increased diagnostic vigilance and more frequent culture for M. abscessus complex.  
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ABSTRACT 
Background: Early signs of pulmonary disease with Mycobacterium abscessus complex 
(MABSC) can be missed in patients with cystic fibrosis (CF), due to subtle presentation, ample 
differential diagnoses and mycobacterial culture being a suboptimal gold standard. A serological 
method could potentially help stratify patients according to risk, a principle which has previously 
been shown clinically useful.  
Objectives: The aim of this article was to test the diagnostic accuracy of a novel multi-antigen 
method for investigating immunoglobulin G (IgG) activity against MABSC.  
Methods: All patients attending the Copenhagen CF Centre were cultured for MABSC during a 
22 month period and then screened in a cross-sectional study of anti-MABSC IgG serum levels 
determined by enzyme-linked immunosorbent assay (ELISA). Culture positive patients had 
stored serum samples examined for antibody kinetics before and after culture conversion. 
Results: 307 CF patients had 3,480 respiratory samples cultured for nontuberculous 
mycobacteria and were then tested with the anti-MABSC IgG ELISA. Patients with pulmonary 
MABSC disease had median anti-MABSC IgG levels six-fold higher than patients with no 
history of NTM infection (434 vs. 64 ELISA units; p < 0.001). Test sensitivity was 95 % (95 % 
CI: 74 – 99) and specificity 73 % (95 % CI: 67 – 78). A diagnostic algorithm was constructed to 
stratify patients according to risk.  
Conclusion:  
The test accurately identified patients with pulmonary disease caused by MABSC and was suited 
to be used clinically as a complement to mycobacterial culture.  
  1 
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INTRODUCTION 2 
Lung infection with nontuberculous mycobacteria (NTM) is a diagnostic and therapeutic 3 
challenge in cystic fibrosis (CF) patients .[1] Mycobacterium abscessus complex (MABSC) is 4 
the dominant NTM in European CF patients and the clinical spectrum varies from colonization to 5 
invasive debilitating disease and identifying patients in need of treatment is essential.[1] New 6 
evidence of increasing incidence rates, human-to-human transmission and a detrimental effect on 7 
lung function has reinvigorated interest in this ubiquitous mycobacteria.[2–4] The pathogenesis 8 
of MABSC is not well understood, but is an urgent research priority as there might be a window 9 
of opportunity for eradication,[5] or suppression,[6] at an early stage of infection. Measuring 10 
anti-MABSC immunoglobulin G (IgG) across whole CF populations could guide clinicians in 11 
deciding how vigilant they have to be in pursuing mycobacterial cultures, a principle, which has 12 
previously been shown useful for Pseudomonas aeruginosa and Aspergillus infection in CF.[7–13 
11] Limitations in the predictive values of such assays have also been reported,[12] and currently 14 
antibody measurements for P. aeruginosa are used clinically in combination with culture results, 15 
rather than as stand-alone tests.[13] Previous experiences with mycobacterial serodiagnosis are 16 
well described in Mycobacterium tuberculosis (TB) research with most studies focusing on 17 
assays utilizing purified single antigens such as M. bovis Calmette-Guérin (BCG) antigen.[14,15] 18 
Other single antigens have also been used,[16] but increasingly the recommended approach is 19 
using a combination of different antigens to improve sensitivity.[17–19] Serodiagnosis for NTM 20 
using the BCG based antigen A60 has been explored twice in CF research,[20,21] showing 21 
promising diagnostic potential.  22 
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The objective of the study was to develop and test the diagnostic accuracy of a novel multi-23 
antigen enzyme-linked immunosorbent assay (ELISA) for measuring anti-MABSC IgG in serum 24 
from a homogenous and well-screened cohort of CF patients. We hypothesized that anti-MABSC 25 
IgG levels were correlated with disease severity and that a useful clinical application could be 26 
developed. The study proceeds in two parts: First we describe antibody serology in CF patients 27 
prospectively screened for MABSC by sputum culture at the Copenhagen CF centre in 2012 – 28 
2014. Secondly we follow the MABSC cases, and describe antibody kinetics before and after 29 
onset of MABSC culture conversion.  30 
 31 
METHODS 32 
Patients and setting 33 
The Copenhagen CF Centre cares for 100 children and 216 adults with CF. Since the 34 
establishment of the centre in 1968, CF patients have been seen for microbiological and clinical 35 
examinations in the outpatient clinic every four weeks. During visits clinical parameters are 36 
registered in a clinical database and serum samples for antibody determination are collected at 37 
least once a year and stored at -80° C for further investigation. 38 
Design and inclusion 39 
All CF patients registered at the Copenhagen CF centre in May 2012 were eligible. Patients were 40 
consecutively enrolled during visits at the adult and paediatric outpatient clinics and admissions 41 
to the CF wards from May 2012 until February 2014. Between October 2013 and February 2014 42 
a serum sample was collected from each patient for anti-MABSC IgG determination. Patients 43 
who died or were lung transplanted were excluded. By February 2014, the patients were divided 44 
into three groups on the basis of NTM culture results and clinical data captured from patient 45 
records: Group A were patients with MABSC pulmonary disease at the time of serum sampling 46 
6 
 
(MABSC-PD). Group B consisted of patients with previous, but not present MABSC-PD and 47 
patients with past or present infection with another NTM. Group C were patients with no known 48 
history of NTM infection. A group of healthy non-CF subjects (adults and children) was 49 
included as normal, reference persons (Group D).  50 
Longitudinal study of MABSC cases 51 
We applied the ELISA method developed above on previously stored serum samples from all 52 
patients with previous or ongoing MABSC from 1987 onwards. Lung transplanted patients were 53 
not excluded in this analysis of antibody kinetics, before, during and after MABSC infection.  54 
NTM disease classification 55 
The CF Centre uses the American Thoracic Society and Infectious Disease Society of America 56 
(ATS/IDSA)’s criteria to classify NTM patients.[22] In this paper we use the term MABSC-PD 57 
to describe patients, who fulfilled both the ATS/IDSA’s clinical, radiological and 58 
microbiological criteria for pulmonary disease. We defined clearing MABSC-PD as 12 months 59 
of culture negativity after culture conversion to negative (based on at least four separate MABSC 60 
negative cultures).  61 
Respiratory samples and isolates  62 
Sputum samples/laryngeal suction samples were collected and Burkholderia cepacia selective 63 
agar (BCSA) were used as growth medium according to a previously described method.[23] 64 
Identification of MABSC is described in the data repository. The longitudinal study also relied 65 
on previously collected NTM culture data from 1987 to 2012 according to methods previously 66 
described in detail.[24]  67 
ELISA method  68 
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Mycobacterial antigen preparation is described in detail in the online data repository. Anti-69 
MABSC IgG levels were determined by ELISA, modified from a previously described method 70 
from our laboratory,[7,26] and expressed in ELISA units (EU). The test positivity threshold was 71 
determined using a receiver operating curve (ROC). For validation purposes a commercial 72 
ELISA kit (A60, Anda Biologicals, Strasbourg, France) was also tested.[15] Intraplate, plate-to-73 
plate, and day-to-day variations were performed on samples from 10 patients, covering the 74 
spectrum of high to low antibody titres and were expressed using coefficient of variation (CV) 75 
and standard deviation (SD). Clinical data were extracted from patient files and the Danish CF 76 
registry.  77 
Statistical methods 78 
The manuscript was prepared in accordance the guidelines for reporting studies on diagnostic 79 
accuracy (STARD). Baseline data were reported as medians and interquartile ranges (IQR) for 80 
non-normally distributed continuous variables, and percentages for categorical variables. Group 81 
comparisons were made using Kruskal Wallis non-parametric tests and Dunn’s multiple 82 
comparisons test. Pearson’s correlation coefficient (r) was used to compare A60 and anti-83 
MABSC assays. A p value ≤ 0.05 was considered statistically significant. SPSS version 19.0 84 
(SPSS Inc, Chicago, IL, USA) and GraphPad Prism 6.0 (GraphPad Software, La Jolla, Ca, USA) 85 
was used for data analysis. The study was approved by the Committee on Health Research Ethics 86 
in the Capital Region of Denmark (H-3-2012-098) and the Danish Data Protection Agency 87 
(2007-58-0015). 88 
 89 
RESULTS 90 
A flow diagram of the study design is shown in Fig. 1.  91 
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[Fig. 1 here] 92 
The Copenhagen CF cohort consisted of 316 patients of which 307 were included. From these 93 
patients 3,480 NTM cultures were performed between May 2012 and February 2014. The 94 
average number of cultures per patient was 11 (range: 1 – 23). All 307 patients had one serum 95 
sample collected between Oct. 2013 and Feb. 2014. Characteristics of patients and healthy non-96 
CF controls are presented in Table 1.  97 
Table 1. Characteristics of 307 patients at the Copenhagen cystic fibrosis centre in Feb. 98 
2014 stratified by nontuberculous mycobacteria status and 532 healthy non-CF controls 99 
 100 
 A B C D 
 
MABSC-PD 
 
 
(n = 19) 
Other NTM 
or non-PD 
MABSC 
(n = 36) 
No history 
of NTM 
 
(n = 252) 
Healthy non- 
CF controls§ 
 
(n = 532) 
Median age (IQR), y 21 (15 – 24) 28 (23 – 37) 24 (14 – 37) 30 (15 – 46) * 
Age under 18 years, % 32 17 36 53 
Female, % 53 47 49    52 ** 
Homozygote for Delta 508, % 68 89 63 NA 
Median FEV1 of pred. (IQR), % 80 (63 – 84) 71 (62 – 80) 76 (53 – 94) - 
Chronic Gram- infection, % 58 42 34 NA 
Received NTM treatment, % 58 61 0 NA 
Median positive NTM cultures (IQR) 7 (4 – 16) 4 (1 – 10) 0 NA 
Median time positive for NTM (IQR), y 2 (1 – 5) 2 (1 – 6) 0 NA 
CF = cystic fibrosis, MABSC = M. abscessus complex, PD = pulmonary disease (as defined by ATS/IDSA criteria), 101 
MAC = M. avium complex, NTM = nontuberculous mycobacteria, IQR = interquartile range, FEV1% = forced 102 
expiratory volume in 1 second as percent of predicted for age, height and sex, ATS/IDSA = American Thoracic 103 
Society / Infectious Disease Society of America. * = age missing for 64/250 paediatric and 64/250 adult controls. ** 104 
= sex data missing for 184/282 paediatric controls, § from frozen sera left from a previous study  105 
 106 
Antibody levels in different groups 107 
Median anti-MABSC IgG was four times higher in patients with MABSC-PD than in patients 108 
with another NTM species or non-PD MABSC (p = 0.03) and six times higher than CF patients 109 
without any NTM history (p < 0.001) (Fig. 2). Healthy, non-CF controls had the lowest IgG 110 
levels with 95 % of subjects demonstrating values below 77 EU.  111 
[Fig. 2 here] 112 
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Test performance 113 
For the purpose of evaluating test performance patients with MABSC-PD were defined as cases 114 
and all other CF patients as controls (Groups B and C combined, n = 288). A receiver operating 115 
curve (ROC) was created based on different thresholds of test positivity (Fig. 3). A cut-off of 125 116 
ELISA units was chosen based on its proximity to the upper left corner of the ROC (perfect 117 
classification point), and its high sensitivity, given the intended clinical use of the test, designed 118 
to be used in conjunction with culture (high specificity). Supplementary test performance is 119 
summarized in Table E1 in the online data repository. Comparison with the antigen A60 method 120 
was performed on 39 patient serum samples and revealed good correlation between the two 121 
methods: Pearson’s correlation coefficient (r) was 0.88 (95 % CI: 0.78 – 0.93) (R2 = 0.77, p-122 
value < 0.0001). 123 
[Fig. 3 here] 124 
Reproducibility of the assay 125 
Intraplate, day-to-day and inter-plate variation measurements were 5 %, 16 % and 11 % 126 
respectively (IQR: 3 – 9 %, 10 – 27 % and 5 – 14 %, respectively).  127 
Diagnostic algorithm  128 
A diagnostic algorithm was constructed (Fig. 4), based on the principle of risk stratification. The 129 
premise of the algorithm was one routine serum sample for anti-MABSC IgG measurement per 130 
patient, per year, and compatibility with current ATS/IDSA screening recommendations.[22] 131 
[Fig. 4 here] 132 
Longitudinal study of MABSC cases 133 
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Fig. 5 shows anti-MABSC IgG levels before and after first positive culture in 26 MABSC cases 134 
that fulfilled criteria for MABSC-PD and six patients who only had one positive MABSC 135 
culture.  136 
[Fig. 5 here] 137 
Eleven out of the 26 patients became IgG positive prior to first positive culture. The majority of 138 
these patients (9/11) were found MABSC culture positive pre 2012, when screening was less 139 
frequent. Noticeably, for four of these cases, their first positive MABSC culture was also their 140 
first ever NTM culture. Seven patients (27 %) had increases in antibody titres prior to culture 141 
conversion, despite previous negative NTM cultures, suggesting various degrees of diagnostic 142 
delay. Overall 85 % of patients that went on to develop MABSC-PD had sharp increases in 143 
antibodies either before or after culture positivity validating the diagnostic potential of the test. 144 
Three had slowly rising antibody levels and did not reach the cut-off of 125 EU within three 145 
years of being classified as having MABSC-PD. The majority of patients with only one positive 146 
MABSC culture did not become IgG positive (Fig. 5 B). 147 
Clearing infection 148 
Seven patients received extensive antimycobacterial treatment prior to clearance and two of the 149 
seven were also lung transplanted. Five patients (56 %) had a convincing overlie (+/- 12 months) 150 
of falling IgG levels and time of clearance, defined as 12 months of culture negativity in at least 151 
four cultures. Two remained antibody positive, despite consistently being culture negative and 152 
having clinical and radiological signs of arrested disease progression (Fig 5 C).  153 
 154 
DISCUSSION 155 
 156 
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The study is the largest examination of antibodies against NTM in CF to date. The primary 157 
strength is the prospective design in a homogeneous and well-screened CF cohort. 158 
 159 
Main findings 160 
In a large centre based cohort of CF patients in Denmark comprehensively screened for NTM 161 
infection, anti-MABSC IgG was found to be significantly elevated in patients with MABSC-PD 162 
and the test demonstrated good diagnostic accuracy. Longitudinal measurements of known 163 
MABSC cases revealed patterns of early antibody kinetics indicative of significant diagnostic 164 
delay, suggesting a potential for earlier intervention. This is the largest study of antibodies 165 
against NTM in CF and key strengths include the prospective design in a homogeneous CF 166 
population screened on a monthly basis. The potential for verification bias [27] was reduced with 167 
an average of 11 cultures per patient and concomitant clinical evaluations. Through the use of 168 
stored serum samples dating back 27 years, the MABSC case study could visualize antibody 169 
kinetics longitudinally, providing a unique opportunity to retrospectively assess MABSC-PD 170 
pathogenesis. Among study weaknesses are the changes in mycobacterial culture techniques and 171 
screening procedures in the period 1987 – 2011. During this period, changing methodology 172 
could confound the overall incidence rates of NTM. Validation wise, intra-plate variation was 173 
good, while inter-plate variation was only acceptable.[31]  174 
Need for improved diagnostic measures  175 
The rise of MABSC in the CF population is of concern and new diagnostic measures are in 176 
demand. Our group recently showed that less than a third of Scandinavian CF patients with 177 
repeated MABSC cultures manage to clear infection and as many as a quarter are lung 178 
transplanted or die.[24] Despite an increased understanding of the pathogenic potential of 179 
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MABSC-PD, diagnostic principles have remained largely unchanged, as have their inherent 180 
obstacles: NTM culture is slow and culture failure is common typically due to insufficient 181 
material or overgrowth of Gram negative bacteria or Aspergillus. Additionally, radiological 182 
pathology is nonspecific in a CF setting.[22]  183 
Immunological tests for mycobacteria 184 
Traditionally, immunological testing for mycobacteria has been based on measurements of 185 
cellular immune responses. Thus, the tuberculin skin test (TST) and later interferon-γ release 186 
assays have been widely used.[28,29] However TST has low sensitivity and is affected by BCG 187 
vaccination and interferon-γ release assay are non-reactive to almost all NTM species and have 188 
no clinical applicability in CF. Serodiagnosis has re-emerged as a field of interest,[17] and two 189 
NTM studies have proposed clinical utility in CF.[20,21] Our results suggest that both our own 190 
ELISA IgG test based on a cocktail of MABSC antigens and a commercially available kit, based 191 
on a purified BCG antigen, are feasible approaches to serodiagnosis for NTM.  192 
Diagnostic delay 193 
The longitudinal study of MABSC cases revealed patterns of early antibody kinetics indicative 194 
of significant diagnostic delay. Martiniano et al.[6] have previously shown that a low FEV1 195 
prior to first positive NTM culture was associated with whether the subsequent infection was 196 
clinically significant. The authors avoid speculating if the causality involved was either poor 197 
lung function leading to increased susceptibility to NTM, or reversely, that non-detected NTM 198 
itself caused the lung function decline in the year leading up to its first isolation (diagnostic 199 
delay). Our study of anti-MABSC IgG kinetics supports the second hypothesis, that NTM itself 200 
is more likely to be the cause of poor lung function. The rise of antibody levels prior to culture 201 
positivity suggests significant, albeit clinically undetected exposure.  202 
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Usefulness of risk algorithm  203 
Serological screening can expedite diagnosis by selectively increasing diagnostic vigilance in 204 
high risk patients. P. aeruginosa serology has proved a useful clinical tool in supporting clinical 205 
decision making.[7,9–11] The principle has limitations,[12] and treatment decisions should not 206 
be based on P. aeruginosa antibody levels alone.[13] In this paper we suggest a risk algorithm 207 
that can selectively increase the mycobacterial culture frequency of patients at highest risk of 208 
MABSC infection. Conventional culture remains the gold standard and is required for the final 209 
diagnosis of MABSC infection. However, an annual serum screening would allow patients to be 210 
stratified according to risk, permitting clinicians to readily differentiate between patients in need 211 
of intensified observation and those who can await routine annual culture. This sequence of first 212 
serum screening, then culture, allows for the optimal combination of high sensitivity (serology) 213 
and subsequent high specificity (culture). This explains our choice of a relatively low positivity 214 
threshold (125 EU) for the IgG screening. While a higher PPV could be achieved at the 400 EU 215 
cut-off, the 125 cut-off had the advantage of minimizing the false negative rate (5 %). The trade 216 
off on PPV is acceptable as antibody screening will always be followed by culture. Applying the 217 
algorithm to our MABSC negative population, 73 % were IgG negative resulting in no clinical 218 
consequence, 23 % had intermediate values between 125 – 400 EU warranting a new antibody 219 
measurement after three-six months to monitor for an increase and just four percent were high 220 
risk patients, who would be subjected to more frequent NTM culturing. With a positive 221 
likelihood ratio of 13 for patients with anti-MABSC IgG over 400 ELISA units, the test fulfils 222 
the prerequisites of a useful diagnostic test for this purpose.[30]  223 
Distinguishing genuine disease from mere colonization has been declared one of the most 224 
important challenges in NTM management,[1] and any objective marker of disease progression, 225 
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that would assist in making this distinction is valuable. Whether the test has other uses, such as 226 
for monitoring treatment effect in patients with MABSC disease, remains to be seen. Certainly, 227 
supplementary disease monitoring methods are in demand as there are currently no good 228 
indicators of MABSC eradication. Culture conversion is necessary, but not sufficient to stop 229 
treatment and relapse is known to occur promptly upon cessation of therapy.[32] MABSC 230 
treatment regiments are exceedingly burdensome, with hearing loss and nephrotoxicity being the 231 
most feared adverse events.[32] Any indicator that could assist in reducing unnecessary long 232 
term treatment is thus welcomed.  233 
 234 
CONCLUSIONS 235 
Antibody levels against M. abscessus complex were significantly elevated in CF patients with 236 
MABSC pulmonary disease. Anti-MABSC IgG screening proved to be an accurate diagnostic 237 
tool and can help clinicians identify CF patients in need of more frequent mycobacterial culture, 238 
thus reducing the problem of diagnostic delay.  239 
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Figure headings 369 
 370 
Fig. 1. Study design. MABSC = M. abscessus complex, MABSC-PD = MABSC pulmonary 371 
disease (as defined by American Thoracic Society / Infectious Disease Society of America 372 
criteria), NTM = nontuberculous mycobacteria 373 
 374 
Fig. 2. Median (IQR) anti-MABSC IgG levels among 3 groups of CF patients (A, B, C) and 375 
healthy non-CF controls (D). Wide horizontal lines = median, short horizontal lines = IQR, 376 
IQR = interquartile range, IgG = immunoglobulin, NTM = nontuberculous mycobacteria, 377 
MABSC = Mycobacterium abscessus complex, PD = pulmonary disease (as defined by the 378 
American Thoracic Society / Infectious Disease Society of America’s criteria), EU = ELISA 379 
Units, AB = combination of group A and B, BC = combination of group B and C. Only non-380 
significant comparison was group B vs. C (p = 0.66).   381 
 382 
Fig. 3. Receiver operating curve (ROC) for anti-Mycobacterium abscessus complex 383 
(MABSC) IgG ELISA. The star represents the chosen cut-off (125 ELISA units). Panel below 384 
shows test characteristics for patients with MABSC pulmonary disease (n = 19) compared to all 385 
other cystic fibrosis patients (n = 288). * = Adjusted analysis where patients with previous 386 
MABSC or another nontuberculous mycobacteria are excluded (n = 252).  387 
 388 
Fig. 4. Diagnostic algorithm employing anti-MABSC IgG levels to stratify CF patients 389 
according to risk of MABSC infection. Raw data, multilevel predictive values and likelihood 390 
ratios are shown in the panel below. 391 
20 
 
 392 
Fig. 5 Anti-Mycobacterium abscessus complex (MABSC) antibody kinetics in serum from 393 
26 cystic fibrosis (CF) patients who develop pulmonary MABSC disease (A) and 6 CF 394 
patients with  only 1 positive MABSC culture (B). C shows anti-MABSC IgG kinetics in 9 395 
CF patients who cleared active pulmonary MABSC infection. In A, B, C the dotted 396 
horizontal line is 125 ELISA units (test positivity threshold). In A and B vertical lines represent 397 
the date of first positive culture, and in C the date of last positive culture before clearance of 398 
MABSC pulmonary disease. Squares represent intravenous courses of amikacin combined with a 399 
carbapenem. Heavy doted lines represent post-lung transplantation data. 400 
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SUPPLEMENTARY METODS 421 
 422 
Mycobacterium abscessus complex (MABSC) identification 423 
Identification of MABSC was based on acid-fast staining followed by identification by both 424 
mass spectrometry (MALDITOFF) and r16RNA gene sequencing. First isolates from each 425 
patient were confirmed by the Reference Laboratory of Mycobacteriology at the State Serum 426 
Institute, Copenhagen, Denmark. 427 
Antigen preparation 428 
Mycobacterial antigen preparation was performed using a M. abscessus sensu stricto serovar 429 
obtained from a patient known to be infected with MABSC. Cells were grown in Souton’s 430 
medium for 2 weeks and harvested by centrifugation, washed in phosphate-buffered saline 431 
(PBS), X-press disrupted at maximal force (200 MPa at -20°C) and then sonicated with a 432 
Sonopuls Ultrasonic Homogenizer (Bandelin, Berlin, Germany) as described by Closs et al. [1] 433 
The protein concentration was set at 2.67 mg/ml as determined by refractometry (Atago, Tokyo, 434 
Japan). The antigen preparation was stored at -80° C. 435 
Supplementary ELISA method  436 
The measured (mean of double determinations) optical density (OD) values of sera were 437 
transformed to EU through the use of a standard curve plotting the titre of pooled sera from 438 
known MABSC cases in eight dilutions (1:500 to 1:64000). Outlying results were not excluded.  439 
All serum testing was performed by one laboratory technician, with expert level ELISA 440 
experience, who was blinded in regard NTM status. 441 
Longitudinal case study setting 1987 - 2014 442 
28 
 
The patients attending the Copenhagen cystic fibrosis (CF) Centre account for approximately 70 443 
% of the total Danish CF population. Population wide screening for nontuberculous 444 
mycobacteria (NTM) was performed once in 1988. The following 23 years, testing for NTM was 445 
only performed routinely on bronchoalveolar lavage (BAL) fluids. Sputum samples were 446 
cultured for NTM in case of clinical suspicion. In 2011, prior to the present study, systematic 447 
annual NTM screening was introduced, consisting of acid fast microscopy and mycobacterial 448 
culture performed at the International Reference Laboratory of Mycobacteriology at the State 449 
Serum Institute, Copenhagen, Denmark.  450 
Criteria for disease 451 
The American Thoracic Society and Infectious Disease Society of America (ATS/IDSA)’s 452 
criteria to classify NTM patients were: Pulmonary symptoms, nodular or cavitatory opacities on 453 
chest radiograph, or a HRCT scan that shows multifocal bronchiectasis with multiple small 454 
nodules after appropriate exclusion of other diagnoses. In addition, positive culture results from 455 
at least two separate sputum samples or positive culture results from at least one bronchoalveolar 456 
lavage. Information from patient files was used to confirm historical NTM cases and classify 457 
when patients fulfilled ATS/IDSA criteria for pulmonary disease (PD).  458 
 459 
RESULTS 460 
Values from CF patients with no known history of NTM were not normally distributed, but 461 
approximated normal distribution after log transformation. Geometric mean values and 462 
confidence intervals for this group and the non-CF controls were 66 EU (95 % CI: 59 – 75) and 463 
32 EU (95 % CI: 31 – 34) respectively. 464 
  465 
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Supplementary Table 466 
 467 
Table E1. Supplementary test characteristics of anti-Mycobacterium abscessus complex IgG 468 
antibody ELISA* using alternative combinations of patient groups 469 
  Group  
AB vs. C 
95 %  
CI 
Group  
AB vs. D 
95 %  
CI 
Group  
A vs. D 
95 %  
CI 
Group  
A vs. BC 
95 % 
CI 
Sens, % 56 (42-70) 56 (42-70) 89 (67-98) 89 (67-98) 
Spec, % 74 (68-79) 98 (96-99) 98 (96-99) 73 (67-78) 
PLR 2.2 (1.6-2.9) 25.0 (13.6-45.8) 40.0 (22.2-70.9) 3.3 (2.6-4.2) 
NLR 0.6 (0.4-0.8) 0.5 (0.3-0.6) 0.1 (0-0.4) 0.2 (0-0.5) 
PPV, % 32 (23-42) 72 (56-85) 59 (39-76) 18 (11-27) 
NPV, % 89 (83-93) 96 (94-97) 100 (99-100) 99 (97-100) 
* = applying the 125 ELISA unit cut-off. Group A = cystic fibrosis (CF) patients with M. abscessus 470 
complex (MABSC) pulmonary disease (PD), Group B = CF patients with other nontuberculous 471 
mycobacteria (NTM) and patients with previous MABSC-PD, Group C = CF patients with no history of 472 
NTM disease, Group D = healthy non-CF controls, IgG = immunoglobulin, ELISA = enzyme-linked 473 
immunosorbent assay, CI = confidence interval, sens = sensitivity, spec = specificity, PLR = positive 474 
likelihood ratio, NLR = negative likelihood ratio, PPV = positive predictive value, NPV = negative 475 
predictive value. 476 
 477 
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